| ATAI Life Sciences |
2.64 B |
Treatments for depression, anxiety, opioid addiction, PTSD with psilocybin, ketamine, DMT, MDMA |
|
| Compass Pathways |
1.56 B |
Psilocybin preparation, derivatives, Mental health treatments |
3 patents granted, 3 published, 2 pending |
| Mind Med |
1.3 B |
Optimize the dosing of MDMA, LSD and other psychedelics based on a patient's profile. |
2 patent applications |
| Seelos Therapeutics |
337 M |
Development of therapies for central nervous system disorders and rare diseases |
1 granted patent |
| Cybin Inc. |
214 M |
Novel compositions of molecules, improved effects for treatments |
2 provisional applications |
| Field Trip Health |
270 M |
Novel psychedelic molecule derived from chemical structures of known substances |
1 provisional application |
| Numinus |
165 M |
Production and distribution of artisanal functional and psychedelic mushrooms |
1 provisional application |
| Revive Therapeutics |
114 M |
Methods of psilocybin production |
2 provisional applications |
| Mydecine |
58 M |
Novel designs of Psilocybin formulations for medical uses and delivery mechanisms for precise dosing |
7 provisional applications |
| Tassili Life Sciences
( acquired by Braxia) |
46 M |
Psilocybin and CBD based therapeutics for PTSD and OCD with timely measured dosing |
4 provisional applications
1 patent granted |
